Topical tacrolimus versus dexamethasone in managing shield ulcer of vernal keratoconjunctivitis

Topical tacrolimus is superior to topical dexamethasone with regard to symptoms, visual acuity, shield ulcer size, and corneal epitheliopathy associated with VKC. This suggests that tacrolimus could be administered as monotherapy for managing this debilitating ocular inflammatory condition. Further studies are required to determine the long-term safety and efficacy of this promising treatment modality.